Skip to Main Content

Harriet Kluger, MD

Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Vice Chair for Translational Research, Internal Medicine; Chief, Division of Skin and Kidney Cancer; Associate Cancer Center Director, Education, Training and Faculty Development; Deputy Section Chief, Medical Oncology

Research Summary

Dr. Kluger is a medical oncologist and the Associate Director for Education, Training and Faculty Development at Yale Cancer Center, and the Deputy Section Chief for Medical Oncology. She sees patients with melanoma and renal cell carcinoma. Approximately half of her time is spent conducting laboratory-based clinical and translational research. She runs an active laboratory focusing on melanoma-related studies, and has been an integral member of the Yale SPORE in Skin Cancer since it was initially awarded in 2006, having co-led four projects during this time. She is currently a Director of the SPORE in Skin Cancer with Dr. Bosenberg. Dr. Kluger collaborates with basic and clinical scientists to develop new approaches for the diseases she treats, including new approaches for patients with brain metastases. Her particular focus is on predictive biomarkers and development of novel therapies, primarily immune activating approaches. She has extensive experience in conducting correlative predictive and prognostic biomarker studies using a variety of technologies, including exome sequencing, expression arrays, tissue microarrays, single cell technologies and others. Her lab conducts pre-clinical targeted drug testing and knock-down studies. She also has experience in designing and conducting clinical trials with laboratory correlates, including investigator initiated trials. All of these trials involve specimen collection (tumor and blood) and analysis. She has been very involved in development of single drug and combination checkpoint regimens, and is well versed with aspects of biomarker development for predicting response to this class of drugs.

Coauthors

Research Interests

Medical Oncology; Melanoma

Selected Publications

Clinical Trials

ConditionsStudy Title
Kidney; Phase IPhase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003
Kidney; Melanoma, skinA Multicenter Phase 2 Trial to Evaluate Intracranial Response to Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Who Are Anti-PD1/PD-L1 Experienced
Phase IA Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, PK, PD, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients With Relapsed or Refractory Solid Tumors
Melanoma, skinA Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma
Phase IA Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Other SkinA Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Lung; Melanoma, skinA Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors
Unknown Sites; Urinary BladderAdvanced Cardiovascular Magnetic Resonance for Detection of Programmed Cell Death Protein-1 Deficient Myocarditis
Melanoma, skinRandomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Brain and Nervous System; Lung; Melanoma, skinA Phase II Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
Phase IA Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Cancers
Melanoma, skinMelanoma Margins Trial-II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (02.18 MelMarT-II)